Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML

CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR... The post Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms appeared first on VJHemOnc.

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring... The post Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! appeared first on VJHemOnc.

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted... The post Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance appeared first on VJHemOnc.

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and... The post Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! appeared first on VJHemOnc.

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly... The post CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes appeared first on VJHemOnc.

Today’s podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar,... The post Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more! appeared first on VJHemOnc.

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH)... The post Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia appeared first on VJHemOnc.

This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 appeared first on VJHemOnc.

In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology... The post Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML appeared first on VJHemOnc.

This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and... The post Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more! appeared first on VJHemOnc.